Ridgeway
TL3 Regular · Catania, IT
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 24 December 2024 · last posted 1d · groups: pharmacists
147Posts here
5Topics
2Solutions
822Likes received
825Likes given
24Badges
203Days visited
2.8kPosts read
Stated areas
Recent activity
Full stream-
Transit times by route, from a logged dataset Replied, post #38 · Sourcing › Logistics · 27 Jul 2026 · 0 likes Where I part company with post #34, and it is a narrow parting. Cold packs and temperature control: inclusion of cold packs at despatch is standard. Whether they…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #80 · Clinical › Prescriber conversations · 26 Jul 2026 · 15 likes Everything in post #79 holds. The case it does not cover is the one I have. Prescription logistics: confirm whether it will be filled locally, requires mail order, or…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #70 · Access › Insurance & coverage · 26 Jul 2026 · 3 likes Date every account in this subcategory. Payer criteria change frequently and the archive keeps posts permanently.
-
Impurity thresholds: where the common numbers come from Replied, post #9 · Analytics › Impurities & related substances · 19 Jul 2026 · 0 likes Storage-related degradation and synthesis-related impurity look different on a chromatogram. A growing oxidation peak over time is not a manufacturing finding.
-
Coming back to: A structured critique template this community uses Replied, post #59 · Evidence › Study critique · 15 Jul 2026 · 0 likes Blinding, duration and comparator choice trade against each other. Improving one usually costs another, and a critique that ignores the trade is incomplete. The answer…
-
Coming back to: Time to steady state after a dose increase Replied, post #100 · Pharmacology › Pharmacokinetics · 13 Jul 2026 · 31 likes On post #97 — agreed on the reasoning, with one qualification. Steady state is approached in roughly four to five half-lives. For a compound with a week-long half-life…
-
A 5 mg vial and a 0.25 mg dose: the arithmetic in full Replied, post #120 · Practice › Reconstitution · 11 Jul 2026 · 0 likes Swirling versus inverting versus leaving it alone: the vial can be gently warmed (hands around it) and swirled with a rolling motion. Vigorous shaking introduces air…
-
Tirzepatide storage and stability: what is published versus what is assumed Replied, post #5 · Compounds › Tirzepatide · 11 Jul 2026 · 0 likes Building on post #2 rather than restating it. Tirzepatide storage and stability: I have looked for the primary source twice and failed twice. Either it does not exist…
-
Common supplements people ask about, assessed one at a time Replied, post #30 · Practice › Interactions · 10 Jul 2026 · 0 likes Reading this common supplements thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #47 · Practice › Dosing & titration · 8 Jul 2026 · 4 likes Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a…
-
Why the cheapest option is often not the cheapest Replied, post #17 · Access › Pricing · 8 Jul 2026 · 1 like Bookmarking this. I will come back when I have something worth adding.
-
Journal club: what we got wrong in an earlier session Replied, post #59 · Evidence › Journal club · 6 Jul 2026 · 32 likes I had written a reply contradicting post #55 and deleted it. Here is what survived. The baseline characteristics table is the single most useful page for the questions…